Skip to main content

Advertisement

Table 4 Statistical comparison of pertinent clinical parameters between subtype IV patients treated with CAF and CMF adjuvant chemotherapy.

From: Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization

  Molecular Subtype IV breast Cancer
  CAF CMF p value*
  Patients (n = 22) Patients (n = 17)  
Age at diagnosis      0.464
< 50 yr 15 68.2% 14 82.4%  
>= 50 yr 7 31.8% 3 17.6%  
TNM Path T      0.612
1 3 13.6% 2 11.8%  
2 19 86.4% 13 76.5%  
3 0 0.0% 1 5.9%  
4 0 0.0% 1 5.9%  
TNM Path N      0.047
0 9 40.9% 11 64.7%  
1 12 54.5% 3 17.6%  
2 1 4.5% 2 11.8%  
3 0 0.0% 1 5.9%  
TNM Path M      0.436
0 22 100.0% 16 94.1%  
1 0 0.0% 1 5.9%  
Positive Lymph Nodes     0.067
0 9 40.9% 11 64.7%  
1-3 12 54.5% 3 17.6%  
4-9 1 4.5% 2 11.8%  
TNM Stage      0.109
I 0 0.0% 2 11.8%  
II 21 95.5% 12 70.6%  
III 1 4.5% 2 11.8%  
IV 0 0.0% 1 5.9%  
Nuclear Grade      0.495
1 1 4.5% 0 0.0%  
2 2 9.1% 0 0.0%  
3 19 86.4% 17 100.0%  
Post-op Radiation Rx     1.000
No 14 63.6% 11 64.7%  
Yes 8 36.4% 6 35.3%  
  1. *: p values were determined by Fisher's exact test.
  2. There was no difference in follow-up duration between two groups (median 9.0 vs. 7.5 years, p = 0.90 by Wilcoxon rank sum test).